Ad-hoc-announcement according to § 15 WpHG

WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE®* (CA9-SCAN)

Munich, 6 June 2008. The Munich-based biopharmaceutical company, WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard), has signed a licensing agreement with IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB / Brussels, Belgium) for the worldwide marketing, distribution and sales of its diagnostic product candidate REDECTANE® (CA9-SCAN). The agreement gives IBA the exclusive global rights and licenses required for manufacturing and marketing the product.

According to the agreement, WILEX will manufacture the cold antibody and be responsible for clinical development. IBA will be responsible for manufacturing by labeling the antibody and will be responsible for distribution, sales and marketing of REDECTANE®. WILEX will receive an upfront payment, milestone payments and certain contributions-in-kind. After the planned market approval, WILEX will get 20% on ex-factory sales until a sales volume of EUR 7 million is reached. After that WILEX will get 45% on total ex-factory sales.

WILEX retains worldwide co-promotion rights and may use these to co-promote REDECTANE® to urologists and oncologists. The companies agreed not to disclose any further details of the agreement. IBA and WILEX had already entered into a manufacturing agreement for the ongoing Phase III registration trial in December 2006.

Due to the conclusion of the agreement WILEX revises its guidance. WILEX now assumes that if projects progress according to plan and no additional inflows of capital are generated, current liquidity could suffice until the second calendar quarter of 2009 rather than the previously announced first calendar quarter of 2009.

* temporary name while under development

Contact
Katja Arnold
Manager Investor Relations
WILEX AG
Grillparzerstr. 10
81675 Munich
Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
Email: investors@WILEX.com
Website: http://www.wilex.com

This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.